Terutroban sodium
Alternative Names: S-18886Latest Information Update: 12 May 2015
At a glance
- Originator Boston University Medical Campus; Servier
- Developer Servier
- Class Anti-ischaemics; Antiplatelets; Antithrombotics; Naphthalenes; Propionic acids; Small molecules
- Mechanism of Action Thromboxane A2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Atherosclerosis; Cerebral ischaemia; Coronary disorders; Peripheral vascular disorders; Thromboembolism
Most Recent Events
- 03 Aug 2010 Servier terminates the phase III PERFORM trial in prevention of Thromboembolism (secondary prevention of ischaemic stroke)
- 27 Jul 2007 Data presented at the 21st Congress of the International Society on Thrombosis and Haemostasis (ISTH-2007) added to the Thromboses pharmacodynamics section
- 12 Jul 2007 Preclinical trials in Arterial thrombosis in France (PO)